Sun Pharma announced on September 28 the signing of an exclusive agreement with US-based LIB Therapeutics covering manufacture, commercialisation and global licensing of Lerodalcibep, an advanced medication designed to control bad cholesterol, across all markets except the United States and China.
Lerodalcibep is a once-monthly PCSK9 inhibitor used to lower low-density lipoprotein cholesterol (LDL-C) in adult patients with hypercholesterolaemia and mixed dyslipidaemia.
